Apalutamide radio-sensitisation of prostate cancer

Br J Cancer. 2021 Nov;125(10):1377-1387. doi: 10.1038/s41416-021-01528-1. Epub 2021 Sep 1.

Abstract

Introduction: The combination of radiotherapy with bicalutamide is the standard treatment of prostate cancer patients with high-risk or locally advanced disease. Whether new-generation anti-androgens, like apalutamide, can improve the radio-curability of these patients is an emerging challenge.

Materials and methods: We comparatively examined the radio-sensitising activity of apalutamide and bicalutamide in hormone-sensitive (22Rv1) and hormone-resistant (PC3, DU145) prostate cancer cell lines. Experiments with xenografts were performed for the 22Rv1 cell line.

Results: Radiation dose-response viability and clonogenic assays showed that apalutamide had a stronger radio-sensitising activity for all three cell lines. Confocal imaging for γΗ2Αx showed similar DNA double-strand break repair kinetics for apalutamide and bicalutamide. No difference was noted in the apoptotic pathway. A striking cell death pattern involving nuclear karyorrhexis and cell pyknosis in the G1/S phase was exclusively noted when radiation was combined with apalutamide. In vivo experiments in SCID and R2G2 mice showed significantly higher efficacy of radiotherapy (2 and 4 Gy) when combined with apalutamide, resulting in extensive xenograft necrosis.

Conclusions: In vitro and in vivo experiments support the superiority of apalutamide over bicalutamide in combination with radiotherapy in prostate cancer. Clinical studies are encouraged to show whether replacement of bicalutamide with apalutamide may improve the curability rates.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anilides / administration & dosage*
  • Anilides / pharmacology
  • Animals
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Chemoradiotherapy
  • Dose-Response Relationship, Radiation
  • Humans
  • Male
  • Mice
  • Nitriles / administration & dosage*
  • Nitriles / pharmacology
  • PC-3 Cells
  • Prostatic Neoplasms / therapy*
  • Radiation-Sensitizing Agents / administration & dosage*
  • Radiation-Sensitizing Agents / pharmacology
  • Thiohydantoins / administration & dosage*
  • Thiohydantoins / pharmacology
  • Tosyl Compounds / administration & dosage*
  • Tosyl Compounds / pharmacology
  • Xenograft Model Antitumor Assays

Substances

  • Anilides
  • Nitriles
  • Radiation-Sensitizing Agents
  • Thiohydantoins
  • Tosyl Compounds
  • apalutamide
  • bicalutamide